Per favore
selezionare il paese

Attenzione, le pagine di questa sezione sono disponibili solo in lingua inglese.

Selezionando la visualizzazione internazionale, l'utente dichiara di risiedere al di fuori degli Stati Uniti e di voler visualizzare le informazioni sui prodotti internazionali di DiaSorin Molecular. Questo materiale è destinato esclusivamente ai visitatori internazionali (non statunitensi) del sito.

Ai sensi delle Linee Guida del Ministero della Salute del 28/03/2013 in materia di pubblicità sanitaria relativa a dispositivi medici, dispositivi medico-diagnostici in vitro e presidi medico-chirurgici, si informa che le informazioni contenute in questo sito e alle quali si accede sono destinate esclusivamente agli operatori professionali.

VERIGENE^® Clostridium difficile Test

Help patients identify and recover from C. difficile infections more quickly

VERIGENE^® Clostridium difficile Test is a rapid, easy-to-use, and cost-effective solution for the identification of toxin-producing C. difficile.

Test diagnostico VERIGENE® per l'identificazione del C. Difficile - Diasorin

Disease state

According to the CDC, Clostridium difficile is now the most common microbial healthcare associated infection (HAI), with annual healthcare costs exceeding $4.8 billion. Approximately 15,000 deaths are attributable to C. difficile infection each year in the US.

Clostridium difficile infections cause symptoms that range from mild diarrhea to the more severe and potentially fatal pseudomembranous colitis

The value of VERIGENE^® Clostridium difficile Test (CDF)

Empower clinicians to rapidly and accurately diagnose C. difficile to ensure appropriate treatment

Proven clinical impact

Rapid identification of C. difficile can help ensure appropriate patient treatment and improve infection control protocols.

Outstanding economic value

Decrease costs by improved infection control measures that reduce the length of stay.

Workflow benefits

The VERIGENE^® System provides an easy-to-use C. difficile test that delivers accurate test results in < 2 hours.

How the VERIGENE^® Clostridium difficile Test works

VERIGENE^® Clostridium difficile is a multiplexed, qualitative test for the rapid detection of toxin A (tcdA), toxin B (tcdB), and tcdC gene sequences of toxigenic C. difficile and for presumptive identification of PCR ribotype 027 strains from unformed (liquid or soft) stool specimens.

Sample-to-answer

Consumables arrive at the laboratory ready to use with no further reagent preparation.

Faster time to results

By simultaneously targeting both the toxin A and toxin B genes and differentiating the 027 strain, VERIGENE^® Clostridium difficile Test delivers comprehensive results directly from a stool sample in less than 2 hours.

Indications for VERIGENE^® Clostridium difficile Test use

System

For use on the VERIGENE^® system as an aid in the diagnosis of C. difficile infections

VERIGENE^® Clostridium difficile Kit

The VERIGENE^® C. difficile (CDF) Test is a rapid, easy-to-use, and cost-effective in vitro diagnostic test for the rapid dection of C. difficile that delivers clinical, economic, and workflow benefits to hospitals and laboratories.

Targets
Toxin A (tcdA gene)
Toxin B (tcdB gene)
PCR Ribotype 027 hypervirulent strain*

^{* For epidemiologic purposes only}

For use with the VERIGENE^® System

The VERIGENE^® System rapidly and accurately detects infectious pathogens. Delivery of this time-critical information allows clinicians to provide targeted patient care more quickly, potentially leading to improved patient outcomes and lower treatment costs. VERIGENE^®’s ease of use makes it a valuable system for use in both hospital-based and reference laboratories.

VERIGENE^® SYSTEM

Offering automated, cost-effective multiplex capabilities.

Discover more